BiondVax Pharmaceuticals Ltd. announced the appointment of Amir Reichman as its new CEO. Mr. Reichman and Ron Babecoff, the company’s founder and current CEO, will share duties during a transition period while Mr. Reichman completes his work obligations at GlaxoSmithKline (GSK). Effective March 2, 2021, Mr. Reichman will assume the CEO position full time and Mr. Babecoff will continue as senior advisor to the company. Born and educated in Israel, Mr. Reichman currently serves as Head of Global Vaccines Engineering Core Technologies and Asset Management at GSK Vaccines headquarters in Belgium. Prior to his current role in global vaccines engineering, he served as Senior Director Global GSK Vaccines Supply Chain. Mr. Reichman joined GSK in 2015 after its acquisition of Novartis Vaccines.